SABS Stock Analysis
SA
Uncovered
SAB Biotherapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Sioux Falls, South Dakota and currently employs 139 full-time employees. The company went IPO on 2021-01-12. The firm is focused on the development of proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. The firm uses its immunotherapy platform, DiversitAb, to produce a new class of specifically targeted, fully human polyclonal antibodies without the need for human donors and applies to a range of serious unmet needs in human diseases. The firm's product candidates include SAB-185, which is a fully human polyclonal antibody therapeutic for the treatment of Coronavirus disease (COVID-19), and SAB-176, a multivalent, neutralizing fully human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. The firm's pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction and early discovery work in oncology.